Wednesday, May 27, 2009

New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance

Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population

THOUSAND OAKS, Calif. – May 27, 2009 – Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as well as emerging antibiotic resistance. Nearly all oncologists surveyed (92 percent) believe it is important for cancer patients to prevent infections to achieve successful treatment outcomes. Antibiotic resistance is a growing concern among the majority of physicians surveyed, with 96 percent of ID specialists and 79 percent of oncologists reporting an increase in antibiotic-resistant infections in cancer patients over the past five years. Both groups of physicians report methicillin-resistant Staphylococcus aureus (MRSA) infections as the most commonly observed in chemotherapy patients.

 

Read the rest of this entry

Posted in Press Releases

Tuesday, May 26, 2009

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET

SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/—Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics’ cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure.

Read the rest of this entry

Posted in Press Releases

Friday, May 15, 2009

Amgen Highlights Data to Be Presented at ASCO

New Vectibix(R) (Panitumumab) Combination Chemotherapy Data

New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients

Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types

THOUSAND OAKS, Calif. – May 15 – Amgen (Nasdaq: AMGN) today announced it will present new data from the Company’s oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. fromMay 29 to June 2, 2009. Data will be presented from several programs, including Vectibix(R) (panitumumab), Neulasta(R) (pegfilgrastim), Aranesp(R) (darbepoetin alfa), denosumab, conatumumab (AMG 655), dulanermin (rhApo2L/TRAIL) and AMG 479.

Read the rest of this entry

Posted in Press Releases, Product News, Pipeline News

Wednesday, May 13, 2009

Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference

THOUSAND OAKS, Calif. – May 13 – Amgen (Nasdaq: AMGN) will present at theDeutsche Bank 34th Annual Healthcare Conference on Monday, May 18, 2009 at the InterContinental,Boston, Mass., beginning at 9:20 a.m. Eastern Time. Chairman and Chief Executive Officer 
Kevin Sharer
will present. Live audio of the presentation will be available over the Internet and can be accessed fromAmgen’s Web site, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases